Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Choosing the best endpoint.

Erik Christensen1

  • 1Department of Medicine I, Division of Gastroenterology, Bispebjerg University Hospital, Copenhagen NV, Denmark. ec05@bbh.regionh.dk

Journal of Hepatology
|August 23, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Developing a comprehensive database and search tool for single-cell ATAC-seq data.

Scientific reports·2026
Same author

Ultrasound-Guided Peripheral Intravenous Access Training: A Prospective Observational Study of Emergency Nurses.

Cureus·2024
Same author

Novel technique for ultrasound-guided needle tracking: An inexpensive reusable phantom model utilising a closed electrical circuit.

Australasian journal of ultrasound in medicine·2024
Same author

Intelligent digital tools for screening of brain connectivity and dementia risk estimation in people affected by mild cognitive impairment: the AI-Mind clinical study protocol.

Frontiers in neurorobotics·2024
Same author

The National Association of Medical Examiners Position Paper on the Investigation and Certification of Pediatric Deaths From Environmental Neglect.

The American journal of forensic medicine and pathology·2024
Same author

Man in Cardiac Arrest.

Annals of emergency medicine·2023
Same journal

A precision randomized trial of hepatitis C treatment support among people who inject drugs in India: The STOP-C Trial.

Journal of hepatology·2026
Same journal

Response to "Single-nucleus and spatial transcriptomic analyses reveal intra-tissue heterogeneity of PNPLA3".

Journal of hepatology·2026
Same journal

One-stop liquid biopsy: Can a single blood sample reveal the full spectrum of liver disease?

Journal of hepatology·2026
Same journal

Nocturnal insulin resistance and reduced insulin availability in human MASLD.

Journal of hepatology·2026
Same journal

Dietary reprogramming of T-cell function enhances anti-cancer immunotherapy efficacy.

Journal of hepatology·2026
Same journal

Alcohol abstinence and recompensation - time to understand the 'how?'

Journal of hepatology·2026
See all related articles

Guidelines for hepatocellular carcinoma (HCC) clinical trials emphasize randomized phase 2 trials with time-to-event endpoints. Survival is key for phase 3, while time to recurrence is suitable for adjuvant settings in HCC research.

Area of Science:

  • Hepatobiliary Cancers
  • Clinical Trial Design
  • Oncology Drug Development

Background:

  • Hepatocellular carcinoma (HCC) trial design is complex due to concurrent liver disease impacting clinical benefit assessment.
  • High-quality clinical trials are urgently needed for hepatocellular carcinoma.
  • An expert panel established guidelines for a standardized HCC trial design framework.

Discussion:

  • Randomized phase 2 trials with time-to-event endpoints (e.g., time to progression) are pivotal for HCC research.
  • Survival is the primary endpoint for phase 3 studies; time to recurrence is proposed for the adjuvant setting.
  • Composite endpoints like progression-free survival may be less reliable in HCC studies.

Key Insights:

  • Target population selection should utilize the Barcelona Clinic Liver Cancer staging system.

Related Experiment Videos

  • New drugs should be tested in patients with well-preserved liver function (Child-Pugh A).
  • Control arms should receive standard-of-care (chemoembolization or sorafenib).

    • Outlook:

    • Further research should integrate biomarkers and molecular imaging into HCC clinical trials.
    • Surrogate markers can enhance study populations and trial cost-benefit ratios.
    • Phase 3 trial design and conduct require coordination by specialized HCC centers.